<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081924</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/1807</org_study_id>
    <nct_id>NCT02081924</nct_id>
  </id_info>
  <brief_title>Reproductive Hormones During Sustained Administration of Kisspeptin</brief_title>
  <acronym>KisspeptPump</acronym>
  <official_title>The Physiological Changes in Reproductive Hormones During Sustained Administration of Kisspeptin in Humans.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to find out what happens to reproductive hormone levels; Luteinising Hormone (LH),
      Follicle Stimulating Hormone (FSH), testosterone and oestradiol when kisspeptin is
      administered to people for a period of 8 days each month, using either placebo (saline) or
      kisspeptin in doses of 0.1, 0.3 or 1.0 nmol/kg/hour.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be invited to have an initial baseline study to look at the hormone levels
      at regular intervals over the course of a day (8hours).

      Following this, on a different day, volunteers will have an infusion of kisspeptin, which
      will be administered by a small pump to deliver the hormone into subcutaneous tissue (fatty
      tissue just below the skin surface). On day 1 of the pump infusion there will be another day
      of regular blood sampling for 8 hours. After this the kisspeptin pump will continue and the
      participants will return to the research unit on day 3 for a review and a single blood test.
      On day 5 the participants will have a review, a blood test and the kisspeptin pump will be
      changed. Kisspeptin infusion will continue and on Day 8 the participant will return for
      another 8 hour study. At the end of this the kisspeptin pump will be removed.

      The above will be repeated using either placebo (saline) or kisspeptin in doses of 0.1, 0.3
      or 1.0 nmol/kg/hour during the early follicular phase of 4 separate menstrual cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2014</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-blinded placebo-controlled study. Women will receive an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles. Luteinising Hormone (LH), Follicle stimulating hormone (FSH) and oestradiol will be measured every 10 min during the infusions.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant won't know whether they are receiving placebo or which dose of kisspeptin</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Kisspeptin on hypothalamic reproductive function - LH levels</measure>
    <time_frame>3 months</time_frame>
    <description>Luteinising hormone levels will be measured at various time-points to assess the effect of kisspeptin on hypothalamic reproductive function, whilst the participant receives a kisspeptin infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Kisspeptin on hypothalamic reproductive function - FSH levels</measure>
    <time_frame>3 months</time_frame>
    <description>FSH levels will be measured at various time-points to assess the effect of kisspeptin on hypothalamic reproductive function, whilst the participant receives a kisspeptin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Kisspeptin on hypothalamic reproductive function - Oestradiol levels</measure>
    <time_frame>3 months</time_frame>
    <description>Oestradiol levels will be measured at various time-points to assess the effect of kisspeptin on hypothalamic reproductive function, whilst the participant receives a kisspeptin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Do participants with normal fertility respond differently to sustained administration of kisspeptin, compared to participants with reduced fertility?</measure>
    <time_frame>3 months</time_frame>
    <description>Reproductive hormone levels (LH, FSH, oestradiol) will be measured at various timepoints, whilst the participant receives a kisspeptin infusion. The results of the two groups will then be compared with one another.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Fertility Disorders</condition>
  <condition>Hypothalamic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Kisspeptin 0.1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kisspeptin 0.3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kisspeptin 1.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kisspeptin 0.1</intervention_name>
    <description>Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.</description>
    <arm_group_label>Kisspeptin 0.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kisspeptin 0.3</intervention_name>
    <description>Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.</description>
    <arm_group_label>Kisspeptin 0.3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kisspeptin 1.0</intervention_name>
    <description>Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.</description>
    <arm_group_label>Kisspeptin 1.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Aged 18-60 years old

          -  Ability to give informed consent

          -  Secondary hypogonadism (or healthy participant)

        Exclusion criteria:

          -  anaemia

          -  medical problems such as severe heart, kidney or liver disease

          -  blood donation in the last three months or intention to donate blood within 3 months
             of the end of the study

          -  needle phobia

          -  Poor venous access

          -  Active psychiatric illness

          -  Severe allergies

          -  Impaired ability to provide full consent to take part in the study

          -  Current alcohol or illicit drug dependence

          -  Current pregnancy or breast feeding

          -  Plans to conceive within 3 months of starting the study (barrier contraception must be
             used during and for 3 months after the end of the study)

          -  Arthritis or any impairment of hand coordination which would preclude using a hormone
             pump
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waljit Dhillo, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ALi Abbara, PhD MRCP</last_name>
    <phone>020 8383 3242</phone>
    <email>ali.abbara@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie A Papadopoulou, BSc MRes</last_name>
    <phone>020 8383 3242</phone>
    <email>d.papadopoulou@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College NHS Healthcare Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waljit Dhillo, PhD, FRCP</last_name>
      <phone>020 8383 3242</phone>
      <email>w.dhillo@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Channa Jayasena, MBBS, PhD</last_name>
      <phone>020 8383 3242</phone>
      <email>c.jayasena@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Waljit Dhillo, PhD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15. Epub 2005 Sep 20.</citation>
    <PMID>16174713</PMID>
  </reference>
  <reference>
    <citation>Dhillo WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson M, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donaldson M, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007 Oct;92(10):3958-66. Epub 2007 Jul 17.</citation>
    <PMID>17635940</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatei MA, Bloom SR, Dhillo WS. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009 Nov;94(11):4315-23. doi: 10.1210/jc.2009-0406. Epub 2009 Oct 9.</citation>
    <PMID>19820030</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Abbara A, Murphy KG, Lim A, Patel D, Mehta A, Todd C, Donaldson M, Trew GH, Ghatei MA, Bloom SR, Dhillo WS. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010 Dec;88(6):840-7. doi: 10.1038/clpt.2010.204. Epub 2010 Oct 27.</citation>
    <PMID>20980998</PMID>
  </reference>
  <reference>
    <citation>Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewki A, Vaal ML, Sriskandarajah L, Murphy KG, Farzad Z, Ghatei MA, Bloom SR, Dhillo WS. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011 Dec;96(12):E1963-72. doi: 10.1210/jc.2011-1408. Epub 2011 Oct 5.</citation>
    <PMID>21976724</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Kisspeptin</keyword>
  <keyword>Reproductive hormones</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

